Poultry pharmaceuticals market size is estimated to be valued at USD 8.7 Bn in 2025 and is expected to reach USD 15.7 Bn in 2032, exhibiting a compound annual growth rate (CAGR) of 8.8% from 2025 to 2032.
The poultry pharmaceuticals market forecast is growing steadily, driven by rising demand for poultry products and the need to improve flock health. Increasing outbreaks of diseases like bird Flu boost the use of vaccines and therapeutics. Regulatory measures, such as the EU’s ban on antibiotic growth promoters, encourage responsible drug use and promote alternative treatments to combat antimicrobial resistance. Technological advancements and stricter food safety standards further support market expansion, making poultry pharmaceuticals essential for sustainable poultry farming worldwide.
|
Event |
Description and Impact |
|
EU Antibiotic Use Restrictions and Global Trade Implications |
|
|
US-China Trade Retaliation Impacting Supply Chains |
|
|
mRNA Vaccine Breakthroughs and Production Scaling |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
In terms of product type, the drugs segment—including Vetrimoxin and other drug products—is expected to dominate the global poultry pharmaceuticals market trend with the share of 55.6% during the forecast period. This dominance is primarily driven by the rising prevalence of zoonotic diseases, which increases the demand for effective therapeutic drug treatments in poultry. Drugs provide direct intervention to control infections, making them a critical component of poultry health management worldwide.
In terms of animal type, the chicken segment is projected to hold the largest share in the global poultry pharmaceuticals market. The segment’s growth is closely linked to the increasing global consumption of chicken meat. As chicken meat production rises, the need for health management solutions to prevent disease outbreaks in chicken flocks escalates, driving demand for poultry pharmaceuticals targeted at chickens.
To learn more about this report, Download Free Sample
North America is projected to dominate the global poultry pharmaceuticals market share, capturing an estimated 38.3% over the forecast period. This leadership is underpinned by the region's heightened focus on managing zoonotic and infectious diseases that directly impact both animal and human health. The strong presence of advanced veterinary pharmaceutical companies, combined with robust regulatory frameworks and increasing public health awareness, drives sustained demand for poultry pharmaceutical products.
For example, according to the World Health Organization, approximately 35,172 human deaths annually in North America are attributed to zoonotic diseases, underscoring the critical need for effective veterinary solutions. Government initiatives to control zoonotic infections further bolster market growth, making North America a pivotal region in the poultry pharmaceuticals sector.
Asia Pacific is anticipated to be one of the fastest-growing regions in the global poultry pharmaceuticals market revenue throughout the forecast period. The region’s growth is fueled by increasing awareness about zoonotic disease prevention, supported by extensive government-led immunization campaigns targeting infectious diseases such as polio and rabies.
Rising investments in animal health infrastructure and growing poultry production in key economies like China, India, and Southeast Asian countries contribute to expanding market opportunities. Enhanced public health initiatives and improved veterinary healthcare access are expected to accelerate the adoption of poultry pharmaceuticals across the region.
The U.S. continues to lead the North American poultry pharmaceuticals market, backed by its strong animal health industry and focus on controlling zoonotic diseases. Significant public health efforts to mitigate infectious outbreaks and the presence of leading pharmaceutical manufacturers are driving demand. Government regulations and funding for disease surveillance and prevention also support the development and adoption of advanced poultry pharmaceutical products.
China is rapidly emerging as a key player in the Asia Pacific poultry pharmaceuticals market, propelled by its large poultry industry and increased governmental focus on animal disease control. Strategic policies promoting veterinary health and the integration of advanced pharmaceutical solutions in poultry farming are accelerating market growth. The country’s expansive production capacity and ongoing efforts to prevent zoonotic diseases contribute to its growing influence within the global market.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 8.7 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 8.8% | 2032 Value Projection: | USD 15.7 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Bayer AG, Bimeda, Ceva Sante Animale, Elanco Animal Health (Eli Lilly and Company), Merck Animal Health, Merial Animal Health (Sanofi), Virbac, Boehringer Ingelheim, Zoetis, Inc., Pacific GeneTech, and Avivagen Inc. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Increasing consumption of chicken is expected to propel growth of the global poultry pharmaceuticals market over the forecast period. Poultry involves raising of birds like ducks, turkeys, chickens and geese for their eggs and meat at domestic or commercial level. Over the decades, the Global poultry pharmaceuticals market has undergone significant transformation, and the region has emerged as one of the major sectors of the economy.
For instance, in July 2021, according to research presented at the 2021 Chicken Marketing Summit, Florida, U.S., 98% of consumers during a two-week survey in the U.S. ate a chicken meal or snack purchased from a supermarket and 68% ate a chicken meal or snack from a food service establishment.
Significant growth of the poultry sector is also expected to aid in growth of the market. For instance, according to a report in November 2022, by the U.S. Poultry and Egg Association, National Chicken Council, National Turkey Federation and United Egg Producers, the study breaks down poultry into three subcategories: chicken, turkey and eggs. The chicken industry provides 1,517,797 jobs, US$ 94.9 billion in wages, US $417 billion in economic activity and US$ 25.5 billion in government revenue repectively.
Major players operating in the global poultry pharmaceuticals market include Bayer AG, Bimeda , Ceva Sante Animale, Elanco Animal Health (Eli Lilly and Company), Merck Animal Health, Merial Animal Health (Sanofi), Virbac, Boehringer Ingelheim, Zoetis, Inc., Pacific GeneTech, and Avivagen Inc.
*Definition: Poultry pharmaceuticals comprise vaccines, feed additive medication, and drugs such as parasiticides, and specialized products used to manage reproductive, metabolic or infectious diseases. Poultry medication is used to treat and prevent some illnesses that have an impact on the health and productivity of the birds.
Share
Share
About Author
Vipul Patil is a dynamic management consultant with 6 years of dedicated experience in the pharmaceutical industry. Known for his analytical acumen and strategic insight, Vipul has successfully partnered with pharmaceutical companies to enhance operational efficiency, cross broader expansion, and navigate the complexities of distribution in markets with high revenue potential.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
Schedule a meeting with report Author
